Symbols / HAE Stock $59.84 -1.06% Haemonetics Corporation

Healthcare • Medical Devices • United States • NYQ
HAE (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Medical Devices
CEO Mr. Christopher A. Simon
Exch · Country NYQ · United States
Market Cap 2.78B
Enterprise Value 3.64B
Income 175.44M
Sales 1.32B
FCF (ttm) 335.05M
Book/sh 19.46
Cash/sh 7.82
Employees 3,023
Insider 10d —
IPO May 10, 1991
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E 16.48
Forward P/E 11.31
PEG 0.92
P/S 2.11
P/B 3.07
P/C —
EV/EBITDA 9.98
EV/Sales 2.76
Quick Ratio 1.04
Current Ratio 1.75
Debt/Eq 134.40
LT Debt/Eq —
EPS (ttm) 3.63
EPS next Y 5.29
EPS Growth 28.40%
Revenue Growth -2.70%
EPS Gr Q/Q 19.30%
Rev Gr Q/Q —
Earnings (next) 2026-05-07
Earnings (prior) 2026-02-05
ROA 6.45%
ROE 19.30%
ROIC —
Gross Margin 60.21%
Oper. Margin 21.01%
Profit Margin 13.31%
Shs Outstand 46.47M
Shs Float 45.93M
Insider Own 1.19%
Instit Own 115.79%
Short Float 5.78%
Short Ratio 2.96
Short Interest 2.00M
52W High 87.32
vs 52W High -31.47%
52W Low 47.32
vs 52W Low 26.46%
Beta 0.36
Impl. Vol. 0.20%
Rel Volume 0.48
Avg Volume 823.03K
Volume 392.93K
Target (mean) $84.60
Tgt Median $87.00
Tgt Low $64.00
Tgt High $108.00
# Analysts 10
Recom Buy
Prev Close $60.48
Price $59.84
Change -1.06%
About

Haemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 tools. It also provides treatment in electrophysiology, critical care, neurocritical care, trauma, burn surgery, spine surgery, and cancer surgery; SavvyWire, a sensor-guided 3-in-1 guidewire for TAVR procedures; and OptoWire, a pressure guidewire that measures fractional flow reserve and diastolic pressure ratio, as well as fiber optic sensor solutions used in medical devices and other critical industrial applications. In addition, the company offers hospital products comprising TEG and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, it provides Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and VASCADE closure products comprising VASCADE 5F, VASCADE 6/7F, VASCADE MVP XL, and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen. The company sells its products through direct sales force, independent distributors, clinical specialists, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$84.60
Mean price target
2. Current target
$59.84
Latest analyst target
3. DCF / Fair value
$129.78
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$59.84
Low
$64.00
High
$108.00
Mean
$84.60

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-04-13 main Mizuho Outperform → Outperform $70
2026-03-11 main Citigroup Neutral → Neutral $70
2026-02-06 main Citigroup Neutral → Neutral $75
2026-02-06 main Mizuho Outperform → Outperform $80
2026-02-06 main Barrington Research Outperform → Outperform $94
2026-02-06 reit BTIG Buy → Buy $88
2026-02-02 main Barrington Research Outperform → Outperform $93
2026-01-12 main Barrington Research Outperform → Outperform $93
2026-01-09 reit BTIG Buy → Buy $88
2025-12-17 main Mizuho Outperform → Outperform $90
2025-12-15 main Baird Outperform → Outperform $99
2025-12-15 down Needham Buy → Hold —
2025-12-12 main JP Morgan Neutral → Neutral $74
2025-12-11 down Citigroup Buy → Neutral $88
2025-11-21 reit BTIG Buy → Buy $88
2025-11-07 main Barrington Research Outperform → Outperform $90
2025-11-07 main Needham Buy → Buy $78
2025-11-06 main BTIG Buy → Buy $88
2025-10-21 main Barrington Research Outperform → Outperform $86
2025-10-07 main Citigroup Buy → Buy $64
News
RSS: Latest HAE news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2025-11-10 KROLL MARK W Director — 1,400 $70.56 $98,784
2025-07-24 ZANE ELLEN M Director — 2,693 $0.00 $0
2025-07-24 KROLL MARK W Director — 2,693 $0.00 $0
2025-07-24 ABERNATHY ROBERT E Director — 2,693 $0.00 $0
2025-07-24 COYLE MICHAEL J Director — 2,693 $0.00 $0
2025-07-24 DOCKENDORFF CHARLES J Director — 2,693 $0.00 $0
2025-07-24 POMEROY CLAIRE Director — 2,693 $0.00 $0
2025-07-24 BRYANT DIANE M Director — 2,693 $0.00 $0
2025-07-24 JOHNSON LLOYD EMERSON Director — 2,693 $0.00 $0
2025-06-05 MILLER LAURIE A Officer — 3,195 $0.00 $0
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-03-31 2024-03-31 2023-03-31 2022-03-31
Total Revenue
1,360.82
+3.95%
1,309.06
+12.01%
1,168.66
+17.67%
993.20
Operating Revenue
1,360.82
+3.95%
1,309.06
+12.01%
1,168.66
+17.67%
993.20
Cost Of Revenue
611.87
-0.91%
617.51
+11.55%
553.56
+13.51%
487.69
Reconciled Cost Of Revenue
544.54
-1.41%
552.32
+12.06%
492.90
+12.70%
437.36
Gross Profit
748.96
+8.30%
691.55
+12.43%
615.10
+21.68%
505.50
Operating Expense
547.77
+5.70%
518.25
+12.80%
459.45
+5.78%
434.36
Research And Development
62.72
+15.22%
54.44
+8.59%
50.13
+7.12%
46.80
Selling General And Administration
436.79
+1.16%
431.78
+14.63%
376.68
+10.74%
340.14
Total Expenses
1,159.64
+2.10%
1,135.75
+12.12%
1,013.01
+9.86%
922.05
Operating Income
201.19
+16.09%
173.30
+11.34%
155.65
+118.77%
71.15
Total Operating Income As Reported
221.82
+34.53%
164.88
+5.67%
156.03
+93.23%
80.75
EBITDA
337.40
+28.73%
262.10
+5.12%
249.34
+39.69%
178.50
Normalized EBITDA
316.77
+17.10%
270.52
+8.66%
248.96
+47.40%
168.89
Reconciled Depreciation
115.59
+18.90%
97.22
+4.19%
93.31
-4.54%
97.75
EBIT
221.82
+34.53%
164.88
+5.67%
156.03
+93.23%
80.75
Total Unusual Items
20.63
+345.05%
-8.42
-2303.93%
0.38
-96.02%
9.60
Total Unusual Items Excluding Goodwill
20.63
+345.05%
-8.42
-2303.93%
0.38
-96.02%
9.60
Special Income Charges
20.63
+345.05%
-8.42
-2303.93%
0.38
-96.02%
9.60
Impairment Of Capital Assets
2.39
-77.05%
10.42
0.00
0.00
Restructuring And Mergern Acquisition
-23.02
0.00
0.00
—
Net Income
167.68
+42.64%
117.56
+1.87%
115.40
+166.05%
43.38
Pretax Income
212.07
+39.64%
151.87
+7.40%
141.40
+122.23%
63.63
Net Non Operating Interest Income Expense
-9.75
+25.13%
-13.02
+11.02%
-14.63
+14.55%
-17.12
Interest Expense Non Operating
9.75
-25.13%
13.02
-11.02%
14.63
-14.55%
17.12
Net Interest Income
-9.75
+25.13%
-13.02
+11.02%
-14.63
+14.55%
-17.12
Interest Expense
9.75
-25.13%
13.02
-11.02%
14.63
-14.55%
17.12
Other Income Expense
20.63
+345.05%
-8.42
-2303.93%
0.38
-96.02%
9.60
Gain On Sale Of Business
0.00
-100.00%
2.00
+423.56%
0.38
-96.02%
9.60
Tax Provision
44.39
+29.40%
34.31
+31.94%
26.00
+28.38%
20.25
Tax Rate For Calcs
0.00
-7.52%
0.00
+22.83%
0.00
-42.20%
0.00
Tax Effect Of Unusual Items
4.31
+326.62%
-1.90
-2807.00%
0.07
-97.70%
3.06
Net Income Including Noncontrolling Interests
167.68
+42.64%
117.56
+1.87%
115.40
+166.05%
43.38
Net Income From Continuing Operation Net Minority Interest
167.68
+42.64%
117.56
+1.87%
115.40
+166.05%
43.38
Net Income From Continuing And Discontinued Operation
167.68
+42.64%
117.56
+1.87%
115.40
+166.05%
43.38
Net Income Continuous Operations
167.68
+42.64%
117.56
+1.87%
115.40
+166.05%
43.38
Normalized Income
151.36
+21.99%
124.07
+7.81%
115.09
+212.50%
36.83
Net Income Common Stockholders
167.68
+42.64%
117.56
+1.87%
115.40
+166.05%
43.38
Diluted EPS
3.31
+44.54%
2.29
+2.23%
2.24
+166.67%
0.84
Basic EPS
3.33
+43.70%
2.32
+2.02%
2.27
+167.44%
0.85
Basic Average Shares
50.33
-0.74%
50.71
-0.15%
50.78
-0.52%
51.05
Diluted Average Shares
50.73
-1.30%
51.40
-0.04%
51.42
+0.13%
51.35
Diluted NI Availto Com Stockholders
167.68
+42.64%
117.56
+1.87%
115.40
+166.05%
43.38
Amortization
48.26
+50.67%
32.03
-1.87%
32.64
-31.16%
47.41
Amortization Of Intangibles Income Statement
48.26
+50.67%
32.03
-1.87%
32.64
-31.16%
47.41
Depreciation Amortization Depletion Income Statement
48.26
+50.67%
32.03
-1.87%
32.64
-31.16%
47.41
Depreciation And Amortization In Income Statement
48.26
+50.67%
32.03
-1.87%
32.64
-31.16%
47.41
Line Item Trend 2025-03-31 2024-03-31 2023-03-31 2022-03-31
Total Assets
2,450.95
+11.63%
2,195.59
+13.48%
1,934.83
+4.04%
1,859.73
Current Assets
934.98
+21.60%
768.90
-0.11%
769.72
+1.81%
756.03
Cash Cash Equivalents And Short Term Investments
306.76
+71.57%
178.80
-37.15%
284.47
+9.62%
259.50
Cash And Cash Equivalents
306.76
+71.57%
178.80
-37.15%
284.47
+9.62%
259.50
Receivables
202.66
-1.89%
206.56
+15.31%
179.14
+12.40%
159.38
Accounts Receivable
202.66
-1.89%
206.56
+15.31%
179.14
+12.40%
159.38
Gross Accounts Receivable
208.96
-1.55%
212.26
+15.31%
184.07
+13.73%
161.85
Allowance For Doubtful Accounts Receivable
-6.30
-10.62%
-5.70
-15.47%
-4.93
-99.27%
-2.48
Inventory
365.14
+15.11%
317.20
+22.29%
259.38
-11.48%
293.03
Raw Materials
128.57
-4.16%
134.15
+16.64%
115.02
+47.75%
77.85
Work In Process
14.96
-3.43%
15.49
+23.19%
12.57
-26.85%
17.19
Finished Goods
221.61
+32.25%
167.56
+27.14%
131.79
-33.44%
197.99
Prepaid Assets
—
—
—
44.13
Other Current Assets
60.41
-8.93%
66.34
+41.95%
46.73
+5.90%
44.13
Total Non Current Assets
1,515.97
+6.26%
1,426.69
+22.45%
1,165.10
+5.56%
1,103.70
Net PPE
284.05
-8.77%
311.36
+0.15%
310.88
+20.27%
258.48
Gross PPE
837.19
-12.72%
959.18
+1.58%
944.22
+8.64%
869.15
Accumulated Depreciation
-553.14
+14.61%
-647.82
-2.29%
-633.33
-3.71%
-610.66
Properties
0.00
0.00
0.00
0.00
Land And Improvements
1.99
-51.94%
4.13
-22.92%
5.36
+3.74%
5.17
Buildings And Improvements
105.08
-15.49%
124.34
-2.58%
127.63
+22.30%
104.36
Machinery Furniture Equipment
312.75
-6.53%
334.60
+5.17%
318.15
+5.96%
300.26
Construction In Progress
22.23
-44.00%
39.69
+35.17%
29.37
-45.22%
53.61
Other Properties
395.15
-13.42%
456.41
-1.57%
463.71
+14.28%
405.75
Goodwill And Other Intangible Assets
1,060.01
+9.14%
971.20
+30.89%
742.00
-4.57%
777.55
Goodwill
604.27
+6.93%
565.08
+21.20%
466.23
-0.23%
467.29
Other Intangible Assets
455.74
+12.22%
406.12
+47.27%
275.77
-11.12%
310.26
Non Current Deferred Assets
7.80
+0.83%
7.74
+47.66%
5.24
+17.30%
4.47
Non Current Deferred Taxes Assets
7.80
+0.83%
7.74
+47.66%
5.24
+17.30%
4.47
Other Non Current Assets
164.11
+20.32%
136.39
+27.50%
106.97
+69.25%
63.20
Total Liabilities Net Minority Interest
1,630.11
+31.93%
1,235.63
+10.64%
1,116.83
+0.59%
1,110.31
Current Liabilities
578.11
+92.46%
300.38
+19.29%
251.82
-43.06%
442.27
Payables And Accrued Expenses
126.42
-17.94%
154.07
+19.99%
128.40
+20.10%
106.91
Payables
67.00
-8.67%
73.36
+14.75%
63.93
+9.52%
58.37
Accounts Payable
67.00
-8.67%
73.36
+14.75%
63.93
+9.52%
58.37
Current Accrued Expenses
59.42
-26.37%
80.71
+25.18%
64.47
+32.83%
48.54
Total Tax Payable
—
—
—
13.91
Current Debt And Capital Lease Obligation
303.56
+2867.62%
10.23
-13.20%
11.78
-94.50%
214.15
Current Debt
303.56
+2867.62%
10.23
-13.20%
11.78
-94.50%
214.15
Other Current Borrowings
—
—
—
214.15
Current Capital Lease Obligation
—
—
—
7.20
Current Deferred Liabilities
43.35
+38.75%
31.24
+3.42%
30.21
+12.68%
26.81
Current Deferred Revenue
43.35
+38.75%
31.24
+3.42%
30.21
+12.68%
26.81
Other Current Liabilities
104.78
-0.06%
104.85
+28.77%
81.42
-13.75%
94.40
Total Non Current Liabilities Net Minority Interest
1,052.00
+12.48%
935.25
+8.12%
865.01
+29.48%
668.04
Long Term Debt And Capital Lease Obligation
921.23
+15.51%
797.56
+5.76%
754.10
+34.80%
559.44
Long Term Debt
921.23
+15.51%
797.56
+5.76%
754.10
+34.80%
559.44
Non Current Deferred Liabilities
62.58
-0.11%
62.64
+73.07%
36.20
+26.00%
28.73
Non Current Deferred Taxes Liabilities
62.58
-0.11%
62.64
+73.07%
36.20
+26.00%
28.73
Other Non Current Liabilities
68.19
-9.12%
75.04
+0.44%
74.72
-6.46%
79.88
Stockholders Equity
820.84
-14.49%
959.96
+17.35%
818.00
+9.15%
749.42
Common Stock Equity
820.84
-14.49%
959.96
+17.35%
818.00
+9.15%
749.42
Capital Stock
0.48
-5.12%
0.51
+0.79%
0.50
-1.37%
0.51
Common Stock
0.48
-5.12%
0.51
+0.79%
0.50
-1.37%
0.51
Share Issued
48.22
-5.06%
50.79
+0.67%
50.45
-1.32%
51.12
Ordinary Shares Number
48.22
-5.06%
50.79
+0.67%
50.45
-1.32%
51.12
Additional Paid In Capital
523.26
-17.55%
634.63
+6.71%
594.71
+3.88%
572.48
Retained Earnings
352.17
-2.30%
360.46
+42.38%
253.17
+25.09%
202.39
Gains Losses Not Affecting Retained Earnings
-55.08
-54.59%
-35.63
-17.28%
-30.38
-17.06%
-25.95
Other Equity Adjustments
-55.08
-54.59%
-35.63
-17.28%
-30.38
-17.06%
-25.95
Total Equity Gross Minority Interest
820.84
-14.49%
959.96
+17.35%
818.00
+9.15%
749.42
Total Capitalization
1,742.07
-0.88%
1,757.52
+11.79%
1,572.10
+20.11%
1,308.87
Working Capital
356.86
-23.83%
468.52
-9.54%
517.91
+65.06%
313.76
Invested Capital
2,045.62
+15.72%
1,767.75
+11.61%
1,583.88
+4.00%
1,523.01
Total Debt
1,224.79
+51.62%
807.79
+5.47%
765.89
-1.00%
773.59
Net Debt
918.02
+45.95%
628.99
+30.65%
481.42
-6.36%
514.09
Capital Lease Obligations
—
—
—
7.20
Net Tangible Assets
-239.18
-2027.89%
-11.24
-114.79%
76.00
+370.21%
-28.12
Tangible Book Value
-239.18
-2027.89%
-11.24
-114.79%
76.00
+370.21%
-28.12
Line Item Trend 2025-03-31 2024-03-31 2023-03-31 2022-03-31
Operating Cash Flow
181.72
-0.01%
181.75
-33.44%
273.06
+58.51%
172.26
Cash Flow From Continuing Operating Activities
181.72
-0.01%
181.75
-33.44%
273.06
+58.51%
172.26
Net Income From Continuing Operations
167.68
+42.64%
117.56
+1.87%
115.40
+166.05%
43.38
Depreciation Amortization Depletion
115.59
+18.90%
97.22
+4.19%
93.31
-4.54%
97.75
Depreciation And Amortization
115.59
+18.90%
97.22
+4.19%
93.31
-4.54%
97.75
Other Non Cash Items
-10.69
-171.35%
14.98
+69.90%
8.82
-54.68%
19.46
Stock Based Compensation
29.64
+4.60%
28.33
+10.75%
25.58
+5.02%
24.36
Provisionand Write Offof Assets
—
9.31
+1302.41%
0.66
+177.12%
-0.86
Asset Impairment Charge
2.39
-77.05%
10.42
+1616.47%
0.61
-92.37%
7.95
Deferred Tax
-5.22
+52.72%
-11.04
-330.80%
4.78
-4.59%
5.01
Deferred Income Tax
-5.22
+52.72%
-11.04
-330.80%
4.78
-4.59%
5.01
Operating Gains Losses
-15.70
-1449.65%
-1.01
-7.42%
-0.94
+90.18%
-9.60
Gain Loss On Sale Of PPE
-15.70
-1449.65%
-1.01
-7.42%
-0.94
—
Change In Working Capital
-101.96
-36.49%
-74.70
-392.91%
25.50
+268.04%
-15.18
Change In Receivables
6.96
+128.75%
-24.19
+0.93%
-24.42
+30.17%
-34.97
Changes In Account Receivables
6.96
+128.75%
-24.19
+0.93%
-24.42
+30.17%
-34.97
Change In Inventory
-64.70
-7.73%
-60.06
-295.29%
30.75
+26.52%
24.31
Change In Prepaid Assets
0.23
+122.99%
-0.98
-158.23%
1.69
-41.18%
2.87
Change In Payables And Accrued Expense
-19.21
-143.08%
44.58
+11.97%
39.82
+421.02%
7.64
Change In Other Working Capital
-25.23
+25.89%
-34.05
-52.44%
-22.33
-48.68%
-15.02
Investing Cash Flow
-161.90
+49.78%
-322.39
-124.21%
-143.79
-66.53%
-86.34
Cash Flow From Continuing Investing Activities
-161.90
+49.78%
-322.39
-124.21%
-143.79
-66.53%
-86.34
Net PPE Purchase And Sale
23.25
+1184.70%
1.81
+12.56%
1.61
-20.47%
2.02
Sale Of PPE
23.25
+1184.70%
1.81
+12.56%
1.61
-20.47%
2.02
Capital Expenditure
-39.28
-3.02%
-38.12
+80.07%
-191.33
-98.25%
-96.51
Capital Expenditure Reported
-39.28
-3.02%
-38.12
+80.07%
-191.33
-98.25%
-96.51
Net Investment Purchase And Sale
-17.14
-10.24%
-15.55
+53.17%
-33.20
0.00
Purchase Of Investment
—
—
-33.20
0.00
Net Business Purchase And Sale
-107.61
+55.60%
-242.35
-12017.60%
-2.00
-124.56%
8.14
Purchase Of Business
-150.91
+38.12%
-243.85
-8456.21%
-2.85
-14.00%
-2.50
Gain Loss On Sale Of Business
—
-2.00
-423.56%
-0.38
+96.02%
-9.60
Net Other Investing Changes
-21.11
+25.06%
-28.17
-134.72%
81.14
—
Financing Cash Flow
108.82
+185.18%
38.16
+138.02%
-100.36
-537.27%
-15.75
Cash Flow From Continuing Financing Activities
108.82
+185.18%
38.16
+138.02%
-100.36
-537.27%
-15.75
Net Issuance Payments Of Debt
447.31
+1084.93%
37.75
+492.21%
-9.62
+45.00%
-17.50
Issuance Of Debt
950.00
+763.64%
110.00
-66.67%
330.00
0.00
Repayment Of Debt
-502.69
-595.76%
-72.25
+78.73%
-339.62
-1840.71%
-17.50
Long Term Debt Issuance
950.00
+763.64%
110.00
-66.67%
330.00
0.00
Long Term Debt Payments
-502.69
-595.76%
-72.25
+78.73%
-339.62
-1840.71%
-17.50
Net Long Term Debt Issuance
447.31
+1084.93%
37.75
+492.21%
-9.62
+45.00%
-17.50
Short Term Debt Issuance
—
—
50.00
0.00
Short Term Debt Payments
—
—
0.00
0.00
Net Short Term Debt Issuance
—
—
0.00
0.00
Net Common Stock Issuance
-225.00
0.00
+100.00%
-75.00
0.00
Common Stock Payments
-225.00
0.00
+100.00%
-75.00
0.00
Repurchase Of Capital Stock
-225.00
0.00
+100.00%
-75.00
0.00
Proceeds From Stock Option Exercised
-1.91
-243.72%
1.33
-81.06%
7.02
+7.16%
6.55
Net Other Financing Charges
-111.58
-12002.39%
-0.92
+95.95%
-22.75
-374.46%
-4.80
Changes In Cash
128.65
+225.53%
-102.48
-454.53%
28.91
-58.81%
70.17
Effect Of Exchange Rate Changes
-0.69
+78.49%
-3.19
+19.08%
-3.94
-32.17%
-2.98
Beginning Cash Position
178.80
-37.15%
284.47
+9.62%
259.50
+34.94%
192.31
End Cash Position
306.76
+71.57%
178.80
-37.15%
284.47
+9.62%
259.50
Free Cash Flow
142.45
-0.82%
143.63
+75.73%
81.73
+7.89%
75.75
Interest Paid Supplemental Data
16.53
-20.89%
20.90
+53.83%
13.59
+119.61%
6.19
Income Tax Paid Supplemental Data
49.29
-6.48%
52.71
+193.35%
17.97
-26.06%
24.30
Sale Of Business
43.29
+2786.07%
1.50
+76.47%
0.85
-92.01%
10.64
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category